Loading
CBI-1214 is an experimental bispecific T cell engager from Cartography Biosciences, in phase 1 trials for microsatellite-stable or MSI-low metastatic colorectal cancer.
CBI-1214 is a bispecific T cell engager from Cartography Biosciences. A bispecific T cell engager that binds LY6G6D on colorectal cancer cells and CD3 on T cells, linking the patient's T cells to the cancer cells to kill them. Its furthest stage is phase 1, for microsatellite-stable or MSI-low metastatic colorectal cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07321106 recruiting, started 15 January 2026. Whether it works in people has not been established unless a trial below reports it.
A bispecific T cell engager that binds LY6G6D on colorectal cancer cells and CD3 on T cells, linking the patient's T cells to the cancer cells to kill them. Connects to CD3.
1.One arm of CBI-1214 binds CD3 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CBI-1214" OR ABSTRACT:"CBI-1214") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CBI-1214, not a curated reading list.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/